Autopsy report · NCT00493766

Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

“Because of a strategic decision by Novartis”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 1 month after it had already started.
• 16 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Hormone Refractory Prostate Cancer

Interventions

LBH589

Participants

16

Sites

5

Countries

United States

Trials that died the same way

• Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
  “Due to strategic reasons” (68% match in meaning)
• Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects
  “Strategic Reasons” (67% match in meaning)
• A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma
  “For Strategic Reasons” (66% match in meaning)
• TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.
  “Strategic decision” (62% match in meaning)
• S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
  “Strategic development reasons” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.